Israel - English - Ministry of Health

novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophthalmic suspension - dexamethasone 1.0 mg/ml; neomycin as sulfate 3,500 iu/ml; polymyxin b sulfate 6000 iu/ml - polymyxin b - polymyxin b - maxitrol is indicated in ocular inflammation when concurrent use of antimicrobial in judged necessary.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dexamethasone 1 mg/g (3 % overage);  ; neomycin sulfate 3500 iu/g; polymyxin b sulfate 6000 iu/g - eye ointment - active: dexamethasone 1 mg/g (3 % overage)   neomycin sulfate 3500 iu/g polymyxin b sulfate 6000 iu/g excipient: lanolin methyl hydroxybenzoate propyl hydroxybenzoate white soft paraffin - maxitrol is indicated in ocular inflammation when concurrent use of an antimicrobial is judged necessary.

Israel - English - Ministry of Health

novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophtalmic ointment - dexamethasone 1 mg/g; neomycin as sulfate 3500 iu/g; polymyxin b sulfate 6000 iu/g - dexamethasone and antiinfectives - dexamethasone and antiinfectives - for the treatment of eye infections which are responsive to steroids, when an antibiotic is also needed.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - neomycin sulphate; dexamethasone; polymyxin b sulphate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - dexamethasone; neomycin sulphate; polymyxin b sulphate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - neomycin sulphate; dexamethasone; polymyxin b sulphate -

United States - English - NLM (National Library of Medicine)

harrow eye, llc - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae , klebsiella /enterobacter species, neisseria species, and pseudomonas aeruginosa . this product does not provide adequate coverage against: serratia marcescens and s treptococci , including streptococcus pneumoniae . maxitrol ® (neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension) is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. maxitrol is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin 3.5 mg in 1 g - ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus   influenzae , klebsiella /enterobacter species, neisseria species, and pseudomonas aeruginosa. this product does not provide adequate coverage against: serratia   marcescens   and streptococci, including

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dexamethasone 1 mg/ml;  ; neomycin sulfate 3500 iu/ml; polymyxin b sulfate 6000 iu/ml - eye drops, suspension - active: dexamethasone 1 mg/ml   neomycin sulfate 3500 iu/ml polymyxin b sulfate 6000 iu/ml excipient: benzalkonium chloride as a solution hydrochloric acid hypromellose polysorbate 20 purified water sodium chloride sodium hydroxide